专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

WO2015059701A9 MICRO-ORGANS PROVIDING SUSTAINED DELIVERY OF A THERAPEUTIC POLYPEPTIDE AND METHODS OF USE THEREOF 审中-公开
标题翻译：提供持续递送治疗性多肽的微量器官及其使用方法
公开(公告)号：WO2015059701A9
公开(公告)日：2015-06-25
申请号：PCT/IL2014050917
申请日：2014-10-22
申请人： MEDGENICS MEDICAL ISRAEL LTD
发明人： SHAPIR NIR , MIARI REEM , STERN BARUCH S , BLUM SHANY , RIMLER AVI
IPC分类号： A61B17/322 , A61K35/36
CPC分类号： A61K38/1816 , A61K31/573 , A61K35/36 , A61K38/21 , A61K38/212 , A61K38/215 , A61K38/217 , A61K48/00 , C07K14/505 , C07K14/56 , C12N5/0625 , C12N15/86 , C12N2510/00
摘要： The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro- organ that comprises a nucleic acid sequence operably linked to one or more regulatory sequences. The present invention is further directed to methods providing sustained expression of therapeutic polypeptides and prolonged therapeutic effects, such as erythropoietin and interferon.
摘要翻译：本发明涉及长效治疗制剂及其使用方法，其中所述制剂包含遗传修饰的微器官，所述微器官包含可操作地连接至一个或多个调控序列的核酸序列。本发明进一步涉及提供治疗性多肽的持续表达和延长的治疗效果的方法，例如促红细胞生成素和干扰素。

72. 发明申请

WO2015081858A1 改良型聚乙二醇化重组人干扰素α 2b及其制备方法审中-公开
公开(公告)号：WO2015081858A1
公开(公告)日：2015-06-11
申请号：PCT/CN2014/092885
申请日：2014-12-03
申请人：北京大学
发明人：周德敏 , 张博 , 陈景贤 , 俞飞 , 张传领 , 司龙龙 , 吴凌
IPC分类号： C07K14/555 , C07K1/107 , C12N15/70 , C12N1/21 , C12N15/10 , C12N15/20 , A61K38/21 , A61K47/48 , A61P31/12 , A61P35/00 , A61P37/02
CPC分类号： A61K38/215 , A61K47/60 , C07K14/56
摘要：提供的是人干扰素，其中至少一个氨基酸残基被取代为Lys-azido。还提供的是聚乙二醇化的人干扰素，其提高了人干扰素的体内稳定性。另外，提供的是该干扰素和其聚乙二醇化的产物的制备方法，其包括使用能够表达tRNAPyl/PylRS的质粒。

73. 发明申请

WO2015066212A2 CALPAIN INHIBITORS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND COLORECTAL CANCER 审中-公开
标题翻译：用于治疗炎症性皮肤病和色素沉着病的卡拉胶抑制剂
公开(公告)号：WO2015066212A2
公开(公告)日：2015-05-07
申请号：PCT/US2014/062960
申请日：2014-10-29
申请人： UNIVERSITY OF HAWAII
发明人： HOFFMANN, Peter
IPC分类号： A61K31/60 , A61K31/573
CPC分类号： A61K38/06 , A61K9/5153 , A61K9/5161 , A61K31/165 , A61K38/215 , A61K45/06 , A61K2300/00
摘要： The present disclosure provides a method of treating colitis and colorectal cancer with a m-calpain selective inhibitor. Also described in this disclosure are pharmaceutical compositions comprising a m-calpain selective inhibitor to inhibit m-calpain activity in tumor cells and other cells in the colon.
摘要翻译：本公开提供了用m-钙蛋白酶选择性抑制剂治疗结肠炎和结肠直肠癌的方法。本公开中还描述的是包含抑制肿瘤细胞和结肠中的其它细胞的m-钙蛋白酶活性的m-钙蛋白酶选择性抑制剂的药物组合物。

74. 发明申请

WO2014163684A1 COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE 审中-公开
标题翻译：用于诱发免疫应答疾病的组合治疗
公开(公告)号：WO2014163684A1
公开(公告)日：2014-10-09
申请号：PCT/US2013/075201
申请日：2013-12-14
申请人： IBC PHARMACEUTICALS, INC.
发明人： CHANG, Chien-Hsing , GOLDENBERG, David, M. , ROSSI, Edmund, A. , ROSSI, Diane
IPC分类号： A61K38/21 , A61K39/00
CPC分类号： A61K38/212 , A61K38/21 , A61K38/215 , A61K2039/505 , C07K16/2803 , C07K16/2809 , C07K16/2887 , C07K2317/31 , A61K2300/00
摘要： The present invention concerns combinations of two or more agents for inducing an immune response to cancer or infectious disease. Agents may include leukocyte redirecting complexes, antibody-drug conjugates, interferons (preferably interferon-a), and/or checkpoint inhibitor antibodies. The leukocyte redirecting complexes have at least one binding site for a leukocyte antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3 x anti-CD 19 bispecific antibody, although antibodies against other leukocyte antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of cells associated with cancer or infectious disease. The cytotoxic immune response is enhanced by co- administration of interferon, checkpoint inhibitor antibody and/or ADC.
摘要翻译：本发明涉及用于诱导对癌症或感染性疾病的免疫应答的两种或更多种试剂的组合。试剂可以包括白细胞重定向复合物，抗体 - 药物偶联物，干扰素（优选干扰素-α）和/或检查点抑制剂抗体。白细胞重定向复合物具有白细胞抗原的至少一个结合位点和病变细胞或病原体上的抗原的至少一个结合位点。优选地，复合物是DNL TM复合物。更优选地，复合物包含双特异性抗体（bsAb）。最优选地，bsAb是抗CD3×抗-CD19双特异性抗体，尽管可以使用针对其它白细胞抗原和/或疾病相关抗原的抗体。复合物能够靶向效应T细胞，NK细胞，单核细胞或嗜中性粒细胞，以诱导与癌症或感染性疾病相关的细胞的白细胞介导的细胞毒性。通过共同施用干扰素，检查点抑制剂抗体和/或ADC来增强细胞毒性免疫应答。

75. 发明申请

WO2013016686A1 TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND INTERFERON-BETA 审中-公开
标题翻译：多药联合治疗多发性硬化症和干扰素
公开(公告)号：WO2013016686A1
公开(公告)日：2013-01-31
申请号：PCT/US2012/048689
申请日：2012-07-27
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , GILGUN, Yossi , TARCIC, Nora
发明人： GILGUN, Yossi , TARCIC, Nora
IPC分类号： A01N43/42 , A61K31/47
CPC分类号： A61K38/215 , A61J1/03 , A61J1/14 , A61K9/0019 , A61K31/47 , A61K31/4704 , A61K45/06 , A61K47/02 , A61K47/18 , A61K47/26 , A61K2300/00
摘要： This invention provides a method of treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the patient laquinimod as an add-on therapy to or in combination with interferon-β. This invention also provides a package and a pharmaceutical composition comprising laquinimod and interferon-β for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with interferon-β in treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and interferon-β in the preparation of a combination for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome.
摘要翻译：本发明提供了一种治疗患有多发性硬化症或呈现临床分离综合征的患者的方法，其包括向患者施用作为附加治疗或与干扰素β联合使用的拉喹莫德。本发明还提供了包含拉喹莫德和干扰素-β的包装和药物组合物，用于治疗患有多发性硬化症或出现临床分离的综合征的患者。本发明还提供了用于作为附加疗法或与干扰素组合用于治疗患有多发性硬化症或呈现临床分离综合征的患者的拉喹莫德。本发明还提供了拉喹莫德和干扰素β在制备用于治疗患有多发性硬化症或呈现临床孤立综合征的患者的组合中的用途。

76. 发明申请

WO2012139058A1 BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF 审中-公开
标题翻译：生物标志物对IFNβ的治疗应答预测及其用途
公开(公告)号：WO2012139058A1
公开(公告)日：2012-10-11
申请号：PCT/US2012/032620
申请日：2012-04-06
申请人： BIOGEN IDEC MA INC. , BUSHNELL, Steven , BUKO, Alexander, Michael , WHALLEY, Eric, Taylor , STEBBINS, Christopher , ZHAO, Zhenming , CADAVID, Diego
发明人： BUSHNELL, Steven , BUKO, Alexander, Michael , WHALLEY, Eric, Taylor , STEBBINS, Christopher , ZHAO, Zhenming , CADAVID, Diego
IPC分类号： G01N33/68
CPC分类号： A61K38/215 , A61K45/06 , G01N33/564 , G01N33/74 , G01N2333/52 , G01N2333/523 , G01N2333/70575 , G01N2800/101 , G01N2800/285 , G01N2800/50 , G01N2800/52
摘要： Methods, assays and kits for the identification, assessment and/or treatment of subject having multiple sclerosis (MS) ( e.g ., a patient with relapsing-remitting multiple sclerosis (RRMS)) are disclosed.
摘要翻译：公开了用于鉴定，评估和/或治疗具有多发性硬化（MS）的受试者（例如，复发性多发性硬化症（RRMS）的患者）的方法，测定和试剂盒。

77. 发明申请

WO2012112007A2 COMPOSITION CONTAINING INDUCER OF SIRT1 EXPRESSION FOR PREVENTING OR TREATING SEPSIS OR SEPTIC SHOCK 审中-公开
标题翻译：含有SIRT1表达诱导剂的组合物，用于预防或治疗脓肿或脓毒性休克
公开(公告)号：WO2012112007A2
公开(公告)日：2012-08-23
申请号：PCT/KR2012001225
申请日：2012-02-17
申请人： STEMDR INC , HAN MYUNG KWAN , YOO CHAE HWA , SONG EUN KYUNG , LEE SEUNG OK
发明人： HAN MYUNG KWAN , YOO CHAE HWA , SONG EUN KYUNG , LEE SEUNG OK
IPC分类号： A61K38/21 , A61P7/08 , A61P9/00
CPC分类号： A61K38/215
摘要： The present invention relates to a composition containing an inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating sepsis or septic shock. The inducer of SIRT1 expression can remarkably reduce the mortality caused by sepsis or septic shock by reducing pro-inflammatory cytokines and increasing anti-inflammatory cytokines. Therefore, the inducer of SIRT1 expression is useful for preventing or treating sepsis or septic shock.
摘要翻译：本发明涉及含有用于预防或治疗败血症或脓毒性休克的SIRT1（沉默交配型信息调节2同源物）表达诱导物的组合物。 SIRT1表达诱导剂通过减少促炎细胞因子和增加抗炎细胞因子可显着降低脓毒症或感染性休克引起的死亡率。因此，SIRT1表达诱导剂可用于预防或治疗败血症或感染性休克。

78. 发明申请

WO2012044684A3 INTERFERON-BETA FOR USE AS MONOTHERAPY OR IN COMBINATION WITH OTHER CANCER THERAPIES 审中-公开
标题翻译： INTERFERON-BETA用于单药治疗或与其他癌症治疗结合使用
公开(公告)号：WO2012044684A3
公开(公告)日：2012-06-28
申请号：PCT/US2011053681
申请日：2011-09-28
申请人： BIOGEN IDEC INC , BAKER DARREN P , JOSEPH INGRID B J K , WANG XINZHONG
发明人： BAKER DARREN P , JOSEPH INGRID B J K , WANG XINZHONG
IPC分类号： C07K1/00
CPC分类号： A61K38/215 , A61K31/166 , A61K31/337 , A61K31/4188 , A61K31/436 , A61K31/44 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K2039/505 , A61K2300/00 , C07K16/22 , C07K2317/24 , C07K2317/76
摘要： This description relates to the use of a polymer-conjugated interferon-beta as monotherapy or in combination with other cancer therapies.
摘要翻译：该描述涉及聚合物缀合的干扰素-β作为单一疗法或与其他癌症疗法组合使用。

79. 发明申请

WO2012035113A1 TYPE-1 INTERFERONS FOR TREATMENT OF MULTIPLE SCLEROSIS 审中-公开
标题翻译：用于治疗多发性硬化症的1型干扰素
公开(公告)号：WO2012035113A1
公开(公告)日：2012-03-22
申请号：PCT/EP2011/066034
申请日：2011-09-15
申请人： VAKZINE PROJEKT MANAGMENT GMBH , OERTELT, Clemens , GRODE, Leander
发明人： OERTELT, Clemens , GRODE, Leander
IPC分类号： A61K38/21 , A61P25/28
CPC分类号： A61K38/215
摘要： The invention relates to the field of multiple sclerosis. More particularly, this invention relates to the treatment of multiple sclerosis using Type-1 interferon.
摘要翻译：本发明涉及多发性硬化症领域。更具体地，本发明涉及使用1型干扰素治疗多发性硬化症。

80. 发明申请

WO2011122923A2 LONG-ACTING INTERFERON BETA FORMULATION USING IMMUNOGLOBULIN FRAGMENT 审中-公开
标题翻译：使用免疫抑制蛋白片段的长效干扰素制剂
公开(公告)号：WO2011122923A2
公开(公告)日：2011-10-06
申请号：PCT/KR2011/002335
申请日：2011-04-04
申请人： HANMI HOLDINGS CO., LTD. , KIM, Dae Jin , KIM, Min Young , KIM, Jin Sun , HONG, Sung Hee , JUNG, Sung Youb , KWON, Se Chang
发明人： KIM, Dae Jin , KIM, Min Young , KIM, Jin Sun , HONG, Sung Hee , JUNG, Sung Youb , KWON, Se Chang
IPC分类号： A61K9/22 , A61K9/20 , A61K38/21 , A61K47/34
CPC分类号： A61K38/215 , A61K47/68 , A61K47/6813 , A61K47/6835 , C07K14/565 , C07K19/00 , C07K2317/52 , C07K2317/732 , C07K2317/734 , C07K2319/30
摘要： The present invention relates to a long-acting interferon beta formulation having improved in vivo duration and stability, comprising an interferon beta conjugate that is prepared by covalently linking interferon beta with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting interferon beta formulation of the present invention maintains in vivo activity of interferon beta at a relatively high level and remarkably increases the serum half-life thereof, thereby being used for various diseases, for which interferon is efficacious.
摘要翻译：本发明涉及具有改善的体内持续时间和稳定性的长效型干扰素β制剂，其包含通过非肽基聚合物共价连接干扰素β与免疫球蛋白Fc区制备的干扰素β偶联物及其制备方法。本发明的长效干扰素β配方维持干扰素β的体内活性在相当高的水平，并显着提高其血清半衰期，从而被用于干扰素有效的各种疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式